2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

Susan M. Goodman, Bryan Springer, Gordon Guyatt, Matthew P. Abdel, Vinod Dasa, Michael George, Ora Gewurz-Singer, Jon T. Giles, Beverly Johnson, Steve Lee, Lisa A. Mandl, Michael A. Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry Brause, Antonia F. Chen, Jeremy Gililland, Mark GoodmanArlene Hurley-Rosenblatt, Kyriakos Kirou, Elena Losina, Ronald MacKenzie, Kaleb D Michaud, Ted R Mikuls, Linda Russell, Alexander Sah, Amy S. Miller, Jasvinder A. Singh, Adolph Yates

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Methods: A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi-step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. Results: The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low- or moderate-quality evidence. Conclusion: This guideline should help decision-making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high-quality direct randomized controlled trial data.

Original languageEnglish (US)
Pages (from-to)1538-1551
Number of pages14
JournalArthritis and Rheumatology
Volume69
Issue number8
DOIs
StatePublished - Aug 2017

Fingerprint

Knee Replacement Arthroplasties
Rheumatic Diseases
Antirheumatic Agents
Hip
Tacrine
Guidelines
Glucocorticoids
Juvenile Arthritis
Patient Preference
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Medication Therapy Management
Time Management
Drug Therapy
Psoriatic Arthritis
Perioperative Period
Group Processes
Ankylosing Spondylitis
Biological Factors
Politics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. / Goodman, Susan M.; Springer, Bryan; Guyatt, Gordon; Abdel, Matthew P.; Dasa, Vinod; George, Michael; Gewurz-Singer, Ora; Giles, Jon T.; Johnson, Beverly; Lee, Steve; Mandl, Lisa A.; Mont, Michael A.; Sculco, Peter; Sporer, Scott; Stryker, Louis; Turgunbaev, Marat; Brause, Barry; Chen, Antonia F.; Gililland, Jeremy; Goodman, Mark; Hurley-Rosenblatt, Arlene; Kirou, Kyriakos; Losina, Elena; MacKenzie, Ronald; Michaud, Kaleb D; Mikuls, Ted R; Russell, Linda; Sah, Alexander; Miller, Amy S.; Singh, Jasvinder A.; Yates, Adolph.

In: Arthritis and Rheumatology, Vol. 69, No. 8, 08.2017, p. 1538-1551.

Research output: Contribution to journalArticle

Goodman, SM, Springer, B, Guyatt, G, Abdel, MP, Dasa, V, George, M, Gewurz-Singer, O, Giles, JT, Johnson, B, Lee, S, Mandl, LA, Mont, MA, Sculco, P, Sporer, S, Stryker, L, Turgunbaev, M, Brause, B, Chen, AF, Gililland, J, Goodman, M, Hurley-Rosenblatt, A, Kirou, K, Losina, E, MacKenzie, R, Michaud, KD, Mikuls, TR, Russell, L, Sah, A, Miller, AS, Singh, JA & Yates, A 2017, '2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty', Arthritis and Rheumatology, vol. 69, no. 8, pp. 1538-1551. https://doi.org/10.1002/art.40149
Goodman, Susan M. ; Springer, Bryan ; Guyatt, Gordon ; Abdel, Matthew P. ; Dasa, Vinod ; George, Michael ; Gewurz-Singer, Ora ; Giles, Jon T. ; Johnson, Beverly ; Lee, Steve ; Mandl, Lisa A. ; Mont, Michael A. ; Sculco, Peter ; Sporer, Scott ; Stryker, Louis ; Turgunbaev, Marat ; Brause, Barry ; Chen, Antonia F. ; Gililland, Jeremy ; Goodman, Mark ; Hurley-Rosenblatt, Arlene ; Kirou, Kyriakos ; Losina, Elena ; MacKenzie, Ronald ; Michaud, Kaleb D ; Mikuls, Ted R ; Russell, Linda ; Sah, Alexander ; Miller, Amy S. ; Singh, Jasvinder A. ; Yates, Adolph. / 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. In: Arthritis and Rheumatology. 2017 ; Vol. 69, No. 8. pp. 1538-1551.
@article{3d70c5e2a86342ab88665cdd2d56b3f2,
title = "2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty",
abstract = "Objective: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Methods: A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi-step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. Results: The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low- or moderate-quality evidence. Conclusion: This guideline should help decision-making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high-quality direct randomized controlled trial data.",
author = "Goodman, {Susan M.} and Bryan Springer and Gordon Guyatt and Abdel, {Matthew P.} and Vinod Dasa and Michael George and Ora Gewurz-Singer and Giles, {Jon T.} and Beverly Johnson and Steve Lee and Mandl, {Lisa A.} and Mont, {Michael A.} and Peter Sculco and Scott Sporer and Louis Stryker and Marat Turgunbaev and Barry Brause and Chen, {Antonia F.} and Jeremy Gililland and Mark Goodman and Arlene Hurley-Rosenblatt and Kyriakos Kirou and Elena Losina and Ronald MacKenzie and Michaud, {Kaleb D} and Mikuls, {Ted R} and Linda Russell and Alexander Sah and Miller, {Amy S.} and Singh, {Jasvinder A.} and Adolph Yates",
year = "2017",
month = "8",
doi = "10.1002/art.40149",
language = "English (US)",
volume = "69",
pages = "1538--1551",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

AU - Goodman, Susan M.

AU - Springer, Bryan

AU - Guyatt, Gordon

AU - Abdel, Matthew P.

AU - Dasa, Vinod

AU - George, Michael

AU - Gewurz-Singer, Ora

AU - Giles, Jon T.

AU - Johnson, Beverly

AU - Lee, Steve

AU - Mandl, Lisa A.

AU - Mont, Michael A.

AU - Sculco, Peter

AU - Sporer, Scott

AU - Stryker, Louis

AU - Turgunbaev, Marat

AU - Brause, Barry

AU - Chen, Antonia F.

AU - Gililland, Jeremy

AU - Goodman, Mark

AU - Hurley-Rosenblatt, Arlene

AU - Kirou, Kyriakos

AU - Losina, Elena

AU - MacKenzie, Ronald

AU - Michaud, Kaleb D

AU - Mikuls, Ted R

AU - Russell, Linda

AU - Sah, Alexander

AU - Miller, Amy S.

AU - Singh, Jasvinder A.

AU - Yates, Adolph

PY - 2017/8

Y1 - 2017/8

N2 - Objective: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Methods: A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi-step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. Results: The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low- or moderate-quality evidence. Conclusion: This guideline should help decision-making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high-quality direct randomized controlled trial data.

AB - Objective: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Methods: A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi-step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. Results: The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low- or moderate-quality evidence. Conclusion: This guideline should help decision-making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high-quality direct randomized controlled trial data.

UR - http://www.scopus.com/inward/record.url?scp=85020881455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020881455&partnerID=8YFLogxK

U2 - 10.1002/art.40149

DO - 10.1002/art.40149

M3 - Article

C2 - 28620948

AN - SCOPUS:85020881455

VL - 69

SP - 1538

EP - 1551

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -